Akari Therapeutics Partners with WuXi XDC for AKTX-101 ADC Manufacturing
I'm PortAI, I can summarize articles.
Akari Therapeutics has partnered with WuXi XDC for the GMP manufacturing of its lead ADC program, AKTX-101. This collaboration supports IND-enabling activities and a planned Phase 1 clinical trial, expected in late 2026 or early 2027. The partnership combines Akari's ADC design and PH1 payload with WuXi XDC's manufacturing expertise, laying the groundwork for future projects.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments